Labcorp Holdings Inc. reported fourth‑quarter 2025 revenue of $3.52 billion, a 5.6% year‑over‑year increase, but the figure fell short of the consensus estimate of $3.56 billion. Diluted earnings per share were $1.98, exceeding the $1.70 consensus, while adjusted earnings per share rose to $4.07, beating the $3.95 estimate by $0.12 or 3.2%. The company’s adjusted EPS growth of 18% from $3.45 in Q4 2024 reflects strong cost control and margin expansion.
Diagnostics revenue climbed 5.5% to $2.73 billion, and Central Laboratory revenue grew 11.1% to $793 million, underscoring continued strength in the company’s core testing businesses. The LaunchPad program’s cost‑efficiency initiatives helped offset working‑capital timing pressures that reduced free cash flow in the quarter.
For 2026, Labcorp guided total revenue of $14.61 billion to $14.79 billion and adjusted EPS of $17.55 to $18.25, a modest upside to prior guidance. The guidance signals management’s confidence in the partner‑of‑choice hospital strategy and the resilience of its specialty‑testing mix.
CEO Adam Schechter said, "In 2025, Labcorp grew revenue over 7% and delivered double‑digit adjusted EPS growth, margin expansion and strong free cash flow. Performance was driven by continued strength in our Diagnostics and Central Laboratory businesses." The statement highlights the company’s focus on operational leverage and strategic partnerships.
Investors reacted cautiously to the revenue miss and broader market dynamics, with some concerns about acquisition timing and the development pipeline. The market’s focus on the revenue shortfall and guidance nuances tempered enthusiasm for the earnings beat.
The results illustrate that while Labcorp’s core diagnostics and laboratory segments continue to expand, top‑line pressure and working‑capital timing remain challenges. The company’s ability to maintain margin expansion and deliver a strong adjusted EPS beat suggests disciplined cost management and a favorable mix of high‑margin specialty tests. The guidance indicates a steady growth trajectory, but the revenue miss and investor concerns point to potential headwinds that could affect future performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.